Data files

This workspace contains all data generated by the combiSOM analysis of patient-matched gene expression, DNA-methylation and copy number variation (CNV) of 121 lower grade glioma (LGG) specimen.

Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas, 61 WHO grade II and 76 WHO grade III tumors.

We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 873 biopsy specimens including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt’s lymphoma (BL), mixed FL/DLBCL lymphomas, primary mediastinal large B-cell lymphoma (PMBL), multiple myeloma (MM), IRF4-rearranged large cell lymphoma, MYC-negative high-grade B-cell lymphomas with Chr. 11q aberration pattern (mnBLL-11q), and Mantle cell lymphoma (MCL).

Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed Methylation profiling of primary tumor samples from 122 patients with cerebral gliomas with WHO grade II and grade III tumors.

Three-dimensional (3D) whole body scanner data of nearly 10,000 participants of a cohort collected from the adult population of Leipzig.

307 single cells cultured from three biopsies of three different patients with a BRAF/NRAS wild type, BRAF mutant/NRAS wild type and BRAF wild type/NRAS mutant melanoma metastasis, respectively

Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed Methylation profiling of primary tumor samples from 122 patients with cerebral gliomas with WHO grade II and grade III tumors.